Repetitive administration of rituximab can achieve and maintain clinical remission in patients with MCD or FSGS.
Thomas Osterholt, Polina Todorova, Lucas Kühne...
https://pubmed.ncbi.nlm.nih.gov/37117201/Actively Recruiting
Led by Prof. Dr. Paul Brinkkoetter · Updated on 2025-09-17
500
Participants Needed
12
Research Sites
260 weeks
Total Duration
Researchers are gathering detailed information on patients with idiopathic nephrotic syndrome, Minimal Change Disease MCD, and Focal Segmental Glomerulosclerosis FSGS through the FOrMe registry. This registry seeks to collect data from about 150 children and 350 adults over 10 years to better understand the causes, diagnosis, and treatment of these kidney disorders. The study includes both kids with idiopathic nephrotic syndrome and adults with biopsy-confirmed MCD or FSGS, addressing gaps caused by the rarity and complexity of these conditions. Participants will be enrolled in two groups pediatric patients up to 18 years old diagnosed with idiopathic nephrotic syndrome or biopsy-proven MCD or FSGS, and adults aged 18 or older with biopsy-confirmed primary or secondary FSGS or MCD. During initial and follow-up visits, biological samples such as blood, urine, DNA, feces, and kidney tissue will be collected and stored in a biobank. Adult and some pediatric patients who undergo kidney biopsy will have their tissue digitally analyzed by experts to assess histopathologic features. Throughout the study, clinical data on demographics, disease course, treatments, quality of life, and related health conditions will be recorded. Researchers will monitor kidney function changes, incidence of kidney failure, death, transplants, and quality of life over 5 to 15 years. The study offers long-term observation with biomaterial access to support future research, helping identify risk factors and predictors for outcomes in these kidney diseases.
CONDITIONS
The FOrMe Registry (The German Focal Segmental Glomerulosclerosis and Minimal Change Disease Registry)
P
Paul T Brinkkoetter, MD
L
Linus A Voelker, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Prof. Dr. Paul Brinkkoetter
Lead Sponsor
German Research Foundation
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 15 years
Participants are observed to collect clinical data, biomaterials, and quality of life information throughout their disease course.
Initial visit and follow-up visits for biosampling and clinical data collection
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Thomas Osterholt, Polina Todorova, Lucas Kühne...
https://pubmed.ncbi.nlm.nih.gov/37117201/Prof. Dr. Paul Brinkkoetter
Lead Sponsor
German Research Foundation
Collaborating Sponsor